Focused On-demand Library for Dynein light chain Tctex-type protein 2B

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q8WW35

UPID:
DYT2B_HUMAN

ALTERNATIVE NAMES:
Tctex1 domain-containing protein 2

ALTERNATIVE UPACC:
Q8WW35; A6NCN5

BACKGROUND:
The Dynein light chain Tctex-type protein 2B, alternatively named Tctex1 domain-containing protein 2, is a key component of the dynein-2 complex. This protein is indispensable for the retrograde transport within cilia and flagella, ensuring the correct movement of cargos along microtubules in concert with the intraflagellar transport system. Its function is critical for maintaining the structural integrity and proper operation of cilia and flagella.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in Short-rib thoracic dysplasia 17, a disease marked by severe skeletal and organ defects, Dynein light chain Tctex-type protein 2B represents a promising target for drug discovery. The exploration of its functions and mechanisms could lead to innovative treatments for a spectrum of ciliopathy-related conditions, marking a significant step forward in personalized medicine.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 1133 of 8789